Senseonics HoldingsSENS
Recorded

Senseonics Holdings 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration29 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

All right, great. Thanks, guys. We are going to get started. Good afternoon. Jon Block with Stifel, and I am happy to welcome back the team from Senseonics. We have Tim Goodnow, CEO, Rick Sullivan, CFO, and Brian Hansen, CCO. These guys put up a really good third quarter, actually just reported last night. Revenue ahead, gross margin ahead, raised guidance for the third time this year. A lot of good things to talk about as they have successfully brought back in the commercial operations in-house, and they are clearly executing. Tim, that might just be a good place to start. Talk to us about third quarter, but also more broadly on the strategy that you sought out several quarters ago to put it in place and how it is unfolding.

Tim GoodnowCEO

Sure. First, thanks for having us. We appreciate the time to be here. Third quarter was, we are obviously really excited about the performance and the demonstration, but it frankly was a culmination of just that. Really, 2025 was a year of transition for us. We had recognized in working with our partner, Ascensia Diabetes Care, that it was time for us to transition all of the commercial responsibilities back inside the organization. 2026 was the implementation of that, and what that really gave us was the ability to own our own destiny, if you will. We were able to make the call. We recognized some time ago that awareness was really the key issue for Eversense, our key product, and that we needed to make the investment in it.

Tim GoodnowCEO

We did that starting in late 2025, and that really led to a good, strong first, second, and now third quarter. As we have given guidance, we expect there to be good performance in the fourth quarter as well. Revenue was really important in the quarter. That drove a nice lift, a nice step up in the gross margins. We announced an important new partnership with a pump integration. We have had a great relationship and great results with Sequel and their twiist product, and now we are going to expand that with the new partners with Beta Bionics. Really good work by the team, but obviously a lot of work went in it to get us here.

Operator

Okay. Importantly, I am guessing you feel it is sustainable and durable going forward. Maybe if you could talk about the biggest positive surprises from bringing the commercial organization in-house. I do not know if this is a little bit for you and a little bit for Brian, but talk to us about biggest positive surprises, and then also maybe just touch on maybe some of the challenges that unfolded as well.

Tim GoodnowCEO

Well, I am sure we will get to it. I will let Brian speak to the positives, because there have been many of them. We continue to do work, of course, on our European integration. That is a little bit behind the way that the approval process went for the U.S. We have now been in market for, frankly, two years. The CE marking now is taking longer to get approval. It is more than a year behind, so that delayed the implementation of the 365 in Europe. We are working on it. The team has done a great job, and we have now got all the transitions in place, but that was probably the one area where we want to continue to make progress, and we certainly will. They are very excited to have the 365 product. It really did turn the corner for us in the U.S., so we are going to see that in Europe as well.

Tim GoodnowCEO

On the positive side, Brian, there have been a lot of them.

Brian HansenChief Commercial Officer

Reducing complexity, right? Reducing, Jon, just the interface between the two companies. Having a board seat at Senseonics and having my President role at Ascensia, I kind of wore that hat, but I also had folks that were forecasting between the companies and working on contracts between the companies and just overall liaison management, and we do not have to do that anymore. So we are not fighting with Rick about forecasts and product and what have you. Bringing that all together, it has just reduced the complexity and increased our efficiency, and it makes life a lot easier, to be honest with you.

Operator

Complexity down, efficiency up. Maybe talk to us also about the sales force and how you are able to retain, I am guessing, successfully both in the U.S. and abroad.

Brian HansenChief Commercial Officer

Yeah, in our remarks yesterday, we've had great retention of our team, and I'm really proud of that. Coming over, they got some equity. They got involved to spend more time with Tim and the management team, which is very beneficial to them. Again, it's a cleaner process, but our team in the U.S. was already a unit to itself, so we essentially changed business cards and computers on January 1. We had to decouple a lot more of the things in Europe, so it became a little bit more complicated and took a little bit longer. Again, not necessarily a negative, just a time function. So they'll be much more productive and very similar to what we've had now for the full year in the U.S., OUS as we enter 2027.

Operator

Okay. Guys, again, if you have any questions, please just throw up your hand. I'm going to plow forward. I'll stick with the U.S. and maybe the growth opportunities. I don't know if you guys have given this metric. We did some survey work several weeks ago. How many physicians approximately are prescribing 365 here in the U.S.?

Tim GoodnowCEO

Yeah. It's in the thousands. I don't know if I have a number off the top of my head. In an individual physician, it's probably north of 5,000. Now, sometimes an account can have multiple physicians at it, so we don't necessarily count it that way. But it's grown significantly over the last year, and really over the last two years with 365, so.

Operator

Obviously you're augmenting that with EON Network as well.

Tim GoodnowCEO

Not from the prescribing side. Remember, the EON Network is- Sorry, I mean the inserting side.

Tim GoodnowCEO

is really on the inserting side, and it is important, especially with Medicare, that those be two distinct entities. Typically what Brian's team is executing on, if somebody comes type 2 from primary care, they are not typically going to do the insertion. That is where EON Care comes in and really we will partner, we will facilitate that connection. The patient that is being seen by that physician will get the script, and then we will do a warm handoff to the EON that is doing the insertion.

Operator

Okay. I will go back to EON. I guess where I was trying to go with this is, when we think about the future growth for Senseonics, how do we break it down between utilization amongst those 5,000 plus current docs that are prescribing versus bringing new docs into the fold? Call it same store sales growth versus a new store. Obviously, the growth rates have been very solid, but how do we think about the contribution from each of those parties going forward?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day